Jasmine Thomas
A5047653671- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Metastasis and carcinoma case studies
- Radiomics and Machine Learning in Medical Imaging
- Nanoplatforms for cancer theranostics
- Photodynamic Therapy Research Studies
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- IL-33, ST2, and ILC Pathways
- Tissue Engineering and Regenerative Medicine
- RNA modifications and cancer
- Epigenetics and DNA Methylation
- Reconstructive Surgery and Microvascular Techniques
- Colorectal Cancer Treatments and Studies
- Urological Disorders and Treatments
- Immunotherapy and Immune Responses
- Estrogen and related hormone effects
Memorial Sloan Kettering Cancer Center
2019-2024
Kettering University
2023-2024
Johnson & Johnson (United States)
2023
University Hospital of Wales
1994-1995
Abstract Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed divergent histomorphology, most commonly squamous differentiation. To define biologic basis for and clinical significance this morphologic heterogeneity, here we perform integrated genomic analyses mixed histology cancers separable We find that differentiation is a marker intratumoral immunologic heterogeneity in patients cancer biomarker intrinsic...
We report updated clinical outcomes from a phase II study of pembrolizumab, trastuzumab, and chemotherapy (PTC) in metastatic esophagogastric cancer conjunction with an independent Memorial Sloan Kettering (MSK) cohort.
Abstract Introduction: Enfortumab Vedotin (EV), an antibody-drug conjugate (ADC) targeting Nectin-4, has emerged as a new standard-of-care for patients with metastatic urothelial cancer (UC). Promising results have also been observed in bladder (BLCA) ADCs HER2. To identify predictive biomarkers of ADC sensitivity, we characterized large and expanding biobank patient-derived organoid (PDO) xenograft (PDX) models Nectin-4 HER2 expression, HER2-targeted sensitivity. Methods: We generated 19...
Vascular targeted photodynamic therapy (VTP) is a nonsurgical tumor ablation approach used to treat early-stage prostate cancer and may also be effective for upper tract urothelial (UTUC) based on preclinical data. Toward increasing response rates VTP, we evaluated its efficacy in combination with concurrent PD-1 inhibitor/OX40 agonist immunotherapy tumor-bearing model.In mice allografted MB-49 UTUC cells, compared the effects of combined VTP those component treatments growth, survival, lung...
558 Background: Fibroblast growth factor 3 (FGFR3) is the most common mutation in UTUC and altered approximately 75% of tumors. Tumors harboring FGFR3 mutations (FGFR3-M) have a T-cell impaired tumor microenvironment (TME) which may explain incomplete response to immune checkpoint blockade. We performed scRNA-seq on 8 untreated tumors further characterize phenotype FGFR3-M Methods: (10x Genomics platform) was tissue specimens from different patients who had not received treatment...
Introduction Immunotherapy is revolutionizing the management of multiple cancer types. However, only a subset patients responds to immunotherapy. One mechanism resistance absence immune infiltrates within tumor. In situ vaccine with local means tumor destruction that can induce immunogenic cell death have been shown enhance T infiltration and increase efficacy checkpoint blockade. Methods Here, we compare three different forms localize therapies: radiation therapy (RT), vascular targeted...
<p>Identifying intratumor clonal selection and associated resistance mechanisms. a, Inferred tumor clones paired pre-treatment post-cycle 2 CAPOX + trastuzumab scRNA-seq demonstrates rapid clearance of highly ERBB2 expression (red) clones, while many lower expressing persisted even expanded. Contraction at the on-treatment timepoint reflects their RECIST response initial follow up imaging timepoint, demonstrating that patient 3, who had highest expression, deepest most durable...
<p>Supplemental Methods</p>
<p>Serial plasma ctDNA in an individual patient demonstrating pre-treatment genomic heterogeneity and selection for resistant clones. Plasma at diagnosis revealed ERBB2 amplification a with HER2+ EG cancer, as well numerous pre-existing resistance mechanisms including EGFR amplification, PIK3CA FGFR3-TACC3 fusion that was not identified on tumor sequencing (Figure 2b).</p>
<p>Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor HER2– but PD-L1 CPS 100 retroperitoneal lymph node neuroendocrine differentiation.</p>
<p>HER2 heterogeneity and RTK alterations are more frequent among patients with shorter PFS. HER2 testing tissue / plasma ctDNA NGS upon progression demonstrate that 8 of 16 (50%) had negative tumors post-treatment, 2 ERBB2 amplified pre-treatment were non-amplified post-treatment. Additionally, in PI3K, cell cycle proteins, Ras-Raf, EGFR, FGFR1/2, MET found progression, potentially associated treatment resistance.</p>
<p>Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival objective rate by cohort. b, Overall cohort.</p>